HURA vs MRK vs JPM vs BMY vs AZN

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 6x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate TuHURA Biosciences, Inc. (HURA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 6x versus AstraZeneca PLC at 26. 7x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: AstraZeneca PLC wins at 0. 78x versus Merck & Co. , Inc. 's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -97. 4% for TuHURA Biosciences, Inc. (HURA). Over 10 years, the gap is even starker: JPM returned +481. 2% versus HURA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 25β versus TuHURA Biosciences, Inc. 's 3. 30β — meaning HURA is approximately 1220% more volatile than MRK relative to the S&P 500. On balance sheet safety, TuHURA Biosciences, Inc. (HURA) carries a lower debt/equity ratio of 2% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Over a 3-year CAGR, AZN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for TuHURA Biosciences, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus 0. 0% for HURA. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, AstraZeneca PLC (AZN) is the more undervalued stock at a PEG of 0. 78x versus Merck & Co. , Inc. 's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8. 5x forward P/E versus 22. 2x for Merck & Co. , Inc. — 13. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMY: 15. 9% to $62. 60.

In this comparison, BMY (4.

6% yield), MRK (2. 9% yield), AZN (1. 9% yield), JPM (1. 8% yield) pay a dividend. HURA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), 2. 9% yield, +160. 5% 10Y return). TuHURA Biosciences, Inc. (HURA) carries a higher beta of 3. 30 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +160. 5%, HURA: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HURA (Healthcare) and MRK (Healthcare) and JPM (Financial Services) and BMY (Healthcare) and AZN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HURA is a small-cap quality compounder stock; MRK is a large-cap deep-value stock; JPM is a large-cap deep-value stock; BMY is a mid-cap deep-value stock; AZN is a large-cap quality compounder stock. MRK, JPM, BMY, AZN pay a dividend while HURA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.